Maravai LifeSciences Holdings, Inc.
MRVI
$3.08
-$0.21-6.38%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -11.83% | -39.69% | -31.73% | -27.00% | -23.72% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -11.83% | -39.69% | -31.73% | -27.00% | -23.72% |
| Cost of Revenue | -4.96% | -2.22% | 2.71% | 2.06% | 5.87% |
| Gross Profit | -25.00% | -82.46% | -74.81% | -70.11% | -50.32% |
| SG&A Expenses | -26.33% | -9.44% | -4.88% | -3.23% | 19.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -16.24% | -6.66% | -1.16% | -0.80% | 12.00% |
| Operating Income | 25.69% | -190.60% | -143.79% | -82.97% | -43,401.64% |
| Income Before Tax | -36.76% | 73.77% | -255.43% | -135.13% | -107.02% |
| Income Tax Expenses | 185.71% | -129.58% | -76.10% | -40.22% | -100.00% |
| Earnings from Continuing Operations | -36.79% | 73.87% | -279.14% | -133.04% | 58.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 35.57% | -74.13% | 250.43% | 116.07% | 401.17% |
| Net Income | -37.74% | 73.67% | -304.44% | -147.93% | 75.55% |
| EBIT | 25.69% | -190.60% | -143.79% | -82.97% | -43,401.64% |
| EBITDA | 48.85% | -5,497.09% | -917.71% | -185.15% | -229.31% |
| EPS Basic | -34.65% | 74.25% | -280.72% | -128.70% | 77.22% |
| Normalized Basic EPS | 2,855.17% | -106.21% | 155.41% | 50.00% | -99.91% |
| EPS Diluted | -34.65% | 74.25% | -280.72% | -128.70% | 77.22% |
| Normalized Diluted EPS | 2,855.17% | -106.21% | 155.41% | 50.00% | -99.91% |
| Average Basic Shares Outstanding | 2.30% | 2.21% | 6.18% | 8.38% | 7.32% |
| Average Diluted Shares Outstanding | 2.30% | 2.21% | 6.18% | 8.38% | 7.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |